Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.
Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In 't Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, de Jager SC, Urbanus RT, Hoefer IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T. Best MG, et al. Among authors: van den broek d, van den heuvel mm. Cancer Cell. 2017 Aug 14;32(2):238-252.e9. doi: 10.1016/j.ccell.2017.07.004. Cancer Cell. 2017. PMID: 28810146 Free PMC article.
Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
van Dorp J, Pipinikas C, Suelmann BBM, Mehra N, van Dijk N, Marsico G, van Montfoort ML, Hackinger S, Braaf LM, Amarante T, van Steenis C, McLay K, Daletzakis A, van den Broek D, van de Kamp MW, Hendricksen K, de Feijter JM, Boellaard TN, Meijer RP, van der Heijden AG, Rosenfeld N, van Rhijn BWG, Jones G, van der Heijden MS. van Dorp J, et al. Among authors: van montfoort ml, van steenis c, van rhijn bwg, van den broek d, van de kamp mw, van der heijden ag, van der heijden ms, van dijk n. Nat Med. 2024 Jan;30(1):304. doi: 10.1038/s41591-023-02500-7. Nat Med. 2024. PMID: 37460757 No abstract available.
Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot.
Moritz R, Muller M, Korse CM, van den Broek D, Baas P, van den Noort V, Ten Hoeve JJ, van den Heuvel MM, van Rossum HH. Moritz R, et al. Among authors: van den noort v, van den broek d, van den heuvel mm, van rossum hh. Clin Chim Acta. 2018 Dec;487:6-14. doi: 10.1016/j.cca.2018.09.015. Epub 2018 Sep 8. Clin Chim Acta. 2018. PMID: 30201371
Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions.
Hummelink K, Muller M, Linders TC, van der Noort V, Nederlof PM, Baas P, Burgers S, Smit EF, Meijer GA, van den Heuvel MM, van den Broek D, Monkhorst K. Hummelink K, et al. Among authors: van den heuvel mm, van den broek d, van der noort v. ERJ Open Res. 2019 Mar 25;5(1):00016-2019. doi: 10.1183/23120541.00016-2019. eCollection 2019 Feb. ERJ Open Res. 2019. PMID: 30918895 Free PMC article.
Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity.
van den Broek D, Hiltermann TJN, Biesma B, Dinjens WNM, 't Hart NA, Hinrichs JWJ, Leers MPG, Monkhorst K, van Oosterhout M, Scharnhorst V, Schuuring E, Speel EM, van den Heuvel MM, van Schaik RHN, von der Thüsen J, Willems SM, de Visser L, Ligtenberg MJL. van den Broek D, et al. Among authors: van den heuvel mm, van schaik rhn, van oosterhout m. Front Oncol. 2020 Jan 22;9:1521. doi: 10.3389/fonc.2019.01521. eCollection 2019. Front Oncol. 2020. PMID: 32039011 Free PMC article. Review.
Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
Beagan JJ, Bach S, van Boerdonk RA, van Dijk E, Thunnissen E, van den Broek D, Weiss J, Kazemier G, Pegtel DM, Bahce I, Ylstra B, Heideman DAM. Beagan JJ, et al. Among authors: van boerdonk ra, van dijk e, van den broek d. Lung Cancer. 2020 Jul;145:173-180. doi: 10.1016/j.lungcan.2020.04.039. Epub 2020 May 11. Lung Cancer. 2020. PMID: 32460198 Free article.
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.
Verheijen RB, van Duijl TT, van den Heuvel MM, Vessies D, Muller M, Beijnen JH, Janssen JM, Schellens JHM, Steeghs N, van den Broek D, Huitema ADR. Verheijen RB, et al. Among authors: van den heuvel mm, van den broek d, van duijl tt. Cancer Chemother Pharmacol. 2021 Feb;87(2):269-276. doi: 10.1007/s00280-021-04230-4. Epub 2021 Jan 23. Cancer Chemother Pharmacol. 2021. PMID: 33484280
88 results